Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam duration of antiretroviral medication (ADAM) study

Lancet

Volumn 352, Issue 9123, 1998, Pages 185-190

  Reijers, Monique H E ^a   Weverling, Gerrit Jan ^a   Jurriaans, Suzanne ^a   Wit, Ferdinand W N M ^a   Weigel, Hugo M ^a   Ten Kate, Reinier W ^b   Mulder, Jan Willem ^c   Frissen, P H Jos ^a   Van Leeuwen, Remko ^a   Reiss, Peter ^a   Schuitemaker, Hanneke ^c   De Wolf, Frank ^a   Lange, Joep M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b N   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 19244367532     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)06193-5     Document Type: Article

References (31)

1. 1 Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-39.
2. 2 Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 724-33.
3. 3 Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients - the INCAS trial. JAMA 1998; 279: 930-37.
4. 4 Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
5. 5 Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS defining events and hospitalizations in 10 French AIDS reference centres: Federation National des Centres de lutte contre le SIDA. AIDS 1997; 11: F101-05.
6. 6 Lange JMA, Richman DD. The limitations of simplicity. Antiviral Therapy 1998; 3: 4-5.
7. 7 Wong JK, Gunthard FG, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94: 12754-59.
8. 8 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-58.
9. 9 Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-64.
10. 10 Notermans DW, Jurriaans S, De Wolf F, et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with rifonavir, lamivudine and zidovudine. AIDS 1998; 12: 167-73.
11. 11 Stellbrink HJ, Eggers C, van Lunzen J, Albrecht H, Greten H. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997, 11: 1655-57.
12. 12 Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS 1997; 11: 895-901.
13. 13 Merry C, Barry MG, Mulcahy F, Halifax KL, Back DJ. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997; 11: F117-20.
14. 14 Sommadossi JP. Nucleoside analogs: similarities and differences. Clin Infect Dis 1993; 16(suppl 1): S7-15
15. 15 World Health Organisation. WHO handbook for reporting results of cancer treatment. Geneva: WHO, 1979.
16. 16 Raffi F, Pialoux G, Brun-Vezinet F, et al. Results of TRILEGE trial, a comparison of three maintenance regimens for HIV infected adults receiving induction therapy with zidovudine (ZDV), lamivudine (3TC) and indinavir (IDV). Fifth national conference on retroviruses and opportunistic infections. Chicago, USA, Feb 1-5, 1998: LB15 (abstr).
17. 17 Havlir DV, Hirsch M, Collier A, et al. Randomized trial of indinavir (IDV) vs zidovudine (ZDV)/lamivudine (3TC) vs IDV/ZDV/3TC maintenance therapy after induction IDV/ZDV/3TC therapy. Fifth national conference on retroviruses and opportunistic infections. Chicago, USA, Feb 1-5, 1998: LB16 (abstr).
18. 18 Radboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is needed to achieve a long term antiretroviral response. AIDS (in press).
19. 19 Emini EA, Holder DJ, Schleif WA, et al. Evidence for the prevention of new HIV-1 infection cycles in patients treated with indinavir plus zidovudine plus lamivudine. Antiviral Therapy 1997; 2: 128 (abstr).
20. 20 Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271: 1582-86.
21. 21 Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (RR-17): 1-19.
22. 22 Hall DB, Montaner JGS, Reiss P, et al. Induction-maintenance antiretroviral therapy: proof of concept. AIDS 1998; 12: F41-44.
23. 23 Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12: F9-14.
24. 24 Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate in antiretroviral naive patients during a quadruple drug combination regimen. AIDS (in press).
25. 25 Weverling GJ, Lange JMA, Jurriaans S, et al. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS (in press).
26. 26 Pialoux G, Fournier S, Moulignier A Poveda JD, Clavel F, Dupont B. Central nervous system (CNS) as sanctuary of HIV 1 in a patient treated with AZT + 3TC + indinavir. Fourth national conference on retroviruses and opportunistic infections. Washington DC, USA, Jan 22-26, 1997: 393 (abstr).
27. 27 Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach J-L, Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995; 39: 2555-59.
28. 28 McLean AR, Nowak MA. Competition between zidovudine-sensitive and zidovudine resistant strains of HIV. AIDS 1992; 6: 71-9.
29. 29 De Jong MD, de Boer RF, de Wolf F, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997; 11: F79-84.
30. 30 Kaufmann D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV cohort Study. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-24.
31. 31 Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-86.